News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

Palivizumab-Controlled Evaluation of Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease

Study Status:

Open for enrollment

Contact Information:

(956) 362-2396

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

This study aims to evaluate the safety and tolerability of MK-1654 compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).


Principal Investigator
Dynio Honrubia, MD
Luis Cantu Jr.
Abbott Nutrition
Type of Trial
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram